Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 21, 2025Revista HematologíaOpen Access

CAR-T cells in hematologic disorders: acute myeloid leukemia - A systematic review of efficacy and safety

View Full Paper
Ask AI
Bookmark
Share

Authors

JBJoaquim BarretoMBMA Rodríguez BrillaMEM. Estrada

Discussion

Loading...

Member takes

Overview

Systematic review reveals CAR-T therapy efficacy and safety in AML, indicating potential advancements.

Key Points

  • CAR-T therapies targeting CLL-1 in AML show promising efficacy with high survival rates.
  • Data indicate a 60% survival response at 6.2 months for adults, with 75% in pediatric patients.
  • The review covered 43 studies to analyze the safety and efficacy of various targeted CAR-T therapies.
  • Significant challenges remain in the broader application of CAR-T therapies due to antigen variability.

Cite This Study

Barreto et al. (2025) studied this question.

synapsesocial.com/papers/68d43afa713b0b5dfea7aa61https://doi.org/10.48057/hematologa.v29i2.631
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interpreting the clinical outcomes to date for AML-directed CAR T cell therapies2025 · 1 citations
  2. 2CLL-1 chimeric antigen receptor T-cells for the treatment of Acute Myeloid Leukemia: A phase 1 clinical trial2025 · 1 citations
  3. 3Exploring CAR cell therapies beyond CAR-T for myeloid malignancies2026
  4. 4Efficacy and Safety of CAR T-cell Therapy in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis2025
  5. 5Chimeric Antigen Receptor T-cell Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: Efficacy, Safety, and Future Directions2025 · 1 citations